X4 Pharmaceuticals (XFOR) Other financing activities (2018 - 2025)
X4 Pharmaceuticals' (XFOR) quarterly Other financing activities came in at $52000.0 in Q4 2025, down 61.48% YoY from $135000.0 in Q4 2024, and down 61.48% on a QoQ basis from $135000.0 in Q4 2024.
X4 Pharmaceuticals (XFOR) Other financing activities (2018 - 2025) Analysis & Trends
X4 Pharmaceuticals (XFOR) has 4 years of Other financing activities data on file, last reported at $52000.0 in Q4 2025.
- Quarterly Other financing activities fell 61.48% year-over-year to $52000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $187000.0 (down 32.0% YoY) and the FY2025 annual result came in at $98000.0, down 66.67% from the prior year.
- Other financing activities retreated to $52000.0 in Q4 2025, from $135000.0 in the prior quarter.
- In the past five years, Other financing activities ranged from a high of $135000.0 in Q4 2024 to a low of $52000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | X4 Pharmaceuticals | 533.17 Mn | 338.08 Mn | 7.19 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 52,000.00 |
| Dec 31, 2025 | 52,000.00 |
| Dec 31, 2024 | 135,000.00 |
| Dec 31, 2024 | 135,000.00 |
| Mar 31, 2019 | 113,000.00 |
| Mar 31, 2019 | 113,000.00 |
| Dec 31, 2018 | 27,000.00 |
| Dec 31, 2018 | 27,000.00 |